التفاصيل البيبلوغرافية
| العنوان: |
Complete Metabolic Response to Combined Immune Checkpoint Inhibition after Progression of Metastatic Colorectal Cancer on Pembrolizumab: A Case Report. |
| المؤلفون: |
Krekeler, Carolin1,2 (AUTHOR) annalen.bleckmann@ukmuenster.de, Wethmar, Klaus1,2 (AUTHOR), Mikesch, Jan-Henrik1,2 (AUTHOR), Kerkhoff, Andrea1,2 (AUTHOR), Menck, Kerstin1,2 (AUTHOR), Lenz, Georg1,2 (AUTHOR), Schildhaus, Hans-Ulrich3,4,5 (AUTHOR), Wessolly, Michael4,5 (AUTHOR), Hoffmann, Matthias W.6 (AUTHOR), Pascher, Andreas7 (AUTHOR), Asmus, Inga8 (AUTHOR), Wardelmann, Eva9 (AUTHOR), Bleckmann, Annalen1,2 (AUTHOR) |
| المصدر: |
International Journal of Molecular Sciences. Aug2023, Vol. 24 Issue 15, p12056. 12p. |
| مصطلحات موضوعية: |
*IMMUNE checkpoint inhibitors, *DNA mismatch repair, *DRUG side effects, *COLORECTAL cancer, *PROGRAMMED cell death 1 receptors, *METASTASIS, *IMMUNE checkpoint proteins, *CETUXIMAB |
| الشركة/الكيان: |
UNITED States. Food & Drug Administration |
| مستخلص: |
DNA mismatch repair deficient (dMMR) and microsatellite instable (MSI) metastatic colorectal cancer (mCRC) can be successfully treated with FDA- and EMA-approved immune checkpoint inhibitors (ICI) pembrolizumab and nivolumab (as single agents targeting the anti-programmed cell death protein-1 (PD-1)) or combinations of a PD-1 inhibitor with ipilimumab, a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)-targeting antibody. The best treatment strategy beyond progression on single-agent ICI therapy remains unclear. Here, we present the case of a 63-year-old male with Lynch-syndrome-associated, microsatellite instability-high (MSI-H) mCRC who achieved a rapid normalization of his tumor markers and a complete metabolic remission (CMR), currently lasting for ten months, on sequential ICI treatment with the combination of nivolumab and ipilimumab followed by nivolumab maintenance therapy after progression on single-agent anti-PD-1 ICI therapy. The therapy was well-tolerated, and no immune-related adverse events occurred. To the best of our knowledge, this is the first case of a sustained metabolic complete remission in an MSI-H mCRC patient initially progressing on single-agent anti-PD-1 therapy. Thus, dMMR mCRC patients might benefit from sequential immune checkpoint regimens even with long-term responses. However, further sophistication of clinical algorithms for treatment beyond progression on single-agent ICI therapy in MSI-mCRC is urgently needed. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder